Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab Consolidation and Monotherapy or Combination in DLBCL
NCT03677154Phase 2Completed
- Sponsor
- Roche
- Start
- May 2019
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of mosunetuzumab in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events, PET-CT Complete Response Rate at Primary Response Assessment and 1 more. Started May 2019; status: completed.
02
Drugs
mosunetuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03677154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03677154.